Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Joe Krupa who wrote (8125)	11/28/2001 8:41:16 PM
From: Joe Krupa	Read Replies (1) \| Respond to of 14101

You've got to like this press release (thanks ticktalker on SH): ********************* news.ft.com Pharmacia bows out of warning label fight By Adrian Michaels in New York Published: November 28 2001 19:53 \| Last Updated: November 28 2001 23:13 Pharmacia on Wednesday signalled that it had given up its fight to boost sales of its flagship arthritis drug by having new warning labels approved by regulators. The US pharmaceuticals company admitted that its long and expensive campaign to sway the US Food and Drug Administration into toning down the warnings on Celebrex had probably failed. The effort involved large extra clinical trials and intensive lobbying of the regulator. However the FDA has for months not issued a ruling and Pharmacia said on Wednesday that the particular warning it wanted taken off the label would "not likely be removed". The move is a blow to the company, which receives over $3bn in sales of Celebrex but has seen the drug's meteoric sales growth slow faster than expected because of concerns over safety and heightened price sensitivity among US patients. It said on Wednesday at an analysts' meeting in New York that the overall market growth for drugs in the same class would be only single digits next year. The company will be boosting growth in part by jettisoning Monsanto, its slower-growing agricultural subsidiary. Pharmacia's frank assessment of the failure of its labelling efforts could also have an impact on Merck, whose drug Vioxx is locked in an intense struggle for market share with Celebrex. Merck has also conducted a large, expensive, trial and been lobbying for a softer warning label on Vioxx. It has also yet to hear from the FDA. Pharmacia said on Wednesday that it thought its rival's labelling efforts would fail. Merck cut its sales estimates for Vioxx in October. Pharmacia has gained a lead over Merck in the battle of the successors to their arthritis drugs. Last week the FDA gave Pharmacia approval to market Bextra, its Celebrex follow-up. The approval came a few months earlier than expected and well ahead of Merck's follow-up. However Pharmacia lost its battle to have Bextra approved as being more effective than Celebrex in tackling pain, a key indication that would have boosted sales. It will have to conduct further clinical studies if it wants to persuade the FDA on pain relief. The company said on Wednesday that after the Monsanto sale it would derive 85 per cent of its revenues from prescription drugs. **********************************

To: Joe Krupa who wrote (8125)	11/30/2001 12:43:52 AM
From: Cal Gary	Respond to of 14101

Kreskin, I say the NR comes between 5:00-5:30 pm, on December 3. Alright, I'll match by taking the 4:30-5:00pm Dec 3rd time slot and bet you the NR will comes out of TO.

To: Joe Krupa who wrote (8125)	12/5/2001 6:14:04 PM
From: PlayTheKing	Read Replies (1) \| Respond to of 14101

Related Quotes DMX.TO DMX.TO 4.20 4.20 +0.15 +0.15 delayed 20 mins - disclaimer Quote Data provided by Reuters Wednesday December 5, 6:08 pm Eastern Time Press Release SOURCE: Dimethaid Research Inc. Dimethaid draws $2.5 million against its financing facility -- Acqua Wellington Agreement extended to May 2002 -- TORONTO, Dec. 5 /CNW/ - Dimethaid Research Inc. (TSE: DMX - news) announced today that the Company has effected a draw pursuant to its January 2001 private placement agreement with Acqua Wellington North American Equities Fund, Ltd. Dimethaid issued Acqua Wellington 676,802 shares of common stock and received net proceeds of $2,500,000. Proceeds are to be used largely to support the continued preparation for a North American launch of PENNSAID(R). "We are very pleased to have extended our agreement with Acqua Wellington for an additional few months, through May, 2002, to continue the flexibility to access funds as necessary, despite some regulatory delays in PENNSAID(R) approval." said Rebecca Keeler, President and CEO. "The market into which PENNSAID(R) will launch is large, at over $8 billion in NSAID sales annually in the United States and Canada." Mrs. Keeler continued. "But more importantly, over 18,000 patients annually die from NSAID-induced fatalities, which underscores the need for a safe, efficacious product like PENNSAID(R)" While regulatory approval is pending for PENNSAID(R), development continues on another application utilizing Dimethaid's transdermal carrier; in the area of onychomycosis (nail fungal infection), the completion of formulation studies have determined the most efficacious active ingredient in fighting this fungal infection. This formulation will now be carried forward into clinical trials with a product to compete in this market, which is estimated to be in excess of US $1 billion. Dimethaid Research Inc. is a pharmaceutical company engaged in the development and commercialization of innovative therapeutic products that offer the potential to minimize the unwanted systemic effects of drug therapy on the body. Dimethaid's proprietary drug delivery technology utilizes the cell's tubule system to deliver drugs cell-to-cell. As a result, patients are able to treat localized conditions, such as osteoarthritis, while limiting the body's absorption of, and associated risks from, the medication. This technology has been applied first to produce PENNSAID(R) Topical Solution. The Company's business development strategy is to leverage its proprietary transdermal delivery technology into additional commercial products. For additional information on the Company, please visit www.dimethaid.com. This release may contain forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors outside management's control that could cause actual results to differ materially from those expressed in the forward-looking statements. A discussion of such risk factors is included in the Company's AIF filed with the OSC and includes, without limitation, risks regarding product development, clinical trials, dependence on third parties for development and licensing arrangements, and risks involving regulatory approval of products, licenses and patents. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect subsequent events or circumstances. For further information Dimethaid Research Inc., Tel. (905) 415-1446, info@dimethaid.com Lippert/Heilshorn & Associates, Kim Golodetz, Tel. (212) 838-3777 Bruce Voss, Tel. (310) 691-7100 Archived images on this organization are available through CNW E-Pix at newswire.ca. Images are free to members of The Canadian Press. To request a free copy of this organization's annual report, please go to newswire.ca and click on reports@cnw. Email this story - Most-emailed articles - Most-viewed articles